Loading
Rigel Pharmaceuticals Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by RODRIGUEZ RAUL R, was filed 13 Jun 2022.
Rigel Pharmaceuticals Inc: what insiders have been doing
Rigel Pharmaceuticals Inc belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). In the past year (20 October 2025 to 20 October 2026), 28 filings came from 9 insiders.
The flow runs one way only: 1 sale worth €63k, from 1 insider, and no purchase. The largest single trade was a sale of €63k by Ali-Jackson Kamil, published on 28 May 2026, equal to 0.0083% of the market capitalisation.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
With 28 filings in twelve months, the company is more active than the median of 22 filings across the 5,455 companies we follow on the same exchange. Since 2021, the database holds 1 purchase and 11 sales by insiders of the company. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists net income at 367.0 m USD.
For comparison within the same sector, see the insider buying recorded at Vivos Inc and Anixa Biosciences Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
91
Thresholds
n/a
Buy Volume
€648,259
1 ops. · all time
Sell Volume
€335,847
11 ops. · all time
Who traded when
BuySaleAli-Jackson Kamil1 sale
David A. Santos1 sale
Dean L. Schorno1 sale
Raul R. Rodriguez1 sale
Raymond J. Furey1 sale
Since the insiders bought
- +111.0%Entry US$7.30 · Close at T+365 US$15.40
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Rigel Pharmaceuticals Inc Buy (bullish), based on 5 analysts. Average price target: US$63.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 221 of 26,281 companies
88.3
score / 100
Value85
Quality92
FCF yld8.8%
Earn yld42%
EV/EBITDA7.0x
ROE127%
Gross mgn93%
Net mgn·
Debt/EBITDA0.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$46.72
Analyst consensus
5 analystsBuy
US$43.00Target US$63.00(+35%)US$85.00
Income statement
RevenueUS$294.3M
Gross profitUS$274.7M93% margin
EBITDAUS$131.6M45% margin
Net incomeUS$367M116.3% margin
Valuation
PER (trailing)2.8x
PER (forward)9.5x
P/Book2.0x
Beta1.19
Balance sheet & cash
Market capUS$864.4M
Total debtUS$53.3M
Free Cash FlowUS$75.7M
Debt / Equity9%
Profitability & ownership
ROE126.9%
ROA15.0%
% insiders3.4%
% institutions92.2%
Last declaration on 3 September 2026
Declarations91 total
2,000 shares@ US$24.200.0054% mcap8.6% of flowCommon StockSEC:0000905148-26-004080:3
2,424 shares@ US$47.500.013% mcap3.4% of flowCommon StockSEC:0000905148-26-004078:0
874 shares@ US$47.500.0046% mcap9.7% of flowCommon StockSEC:0000905148-26-004079:0
928 shares@ US$47.500.0049% mcap7.9% of flowCommon StockSEC:0000905148-26-004080:0
694 shares@ US$12.700.0010% mcap1.6% of flowCommon StockSEC:0000905148-26-004080:1
1,286 shares@ US$24.200.0035% mcap5.6% of flowCommon StockSEC:0000905148-26-004080:4
620 shares@ US$18.700.0013% mcap2.1% of flowCommon StockSEC:0000905148-26-004080:2
877 shares@ US$47.500.0046% mcap12.4% of flowCommon StockSEC:0000905148-26-004077:0
24,400 shares0Common StockSEC:0000905148-26-003238:0
2,500 shares@ US$35.000.011% mcap100.0% of flowCommonSEC144:0001959173-26-004799
2,500 shares@ US$29.170.0083% mcap100.0% of flowCommon StockSEC:0000905148-26-002724:0
5,750 shares0Common StockSEC:0000905148-26-002529:0
4,000 shares@ US$24.00100.0% of flowCommon StockSEC:0000905148-26-001015:0
19,497 shares0Common StockSEC:0000905148-26-000956:0
19,430 shares0Common StockSEC:0000905148-26-000954:0
18,894 shares0Common StockSEC:0000905148-26-000953:0
53,915 shares0Common StockSEC:0000905148-26-000955:0
20,636 shares0Common StockSEC:0000905148-26-000952:0
3,546 shares@ US$34.6227.9% of flowCommon StockSEC:0000905148-26-000679:0
3,758 shares@ US$34.62100.0% of flowCommon StockSEC:0000905148-26-000677:0
3,546 shares@ US$34.6235.7% of flowCommon StockSEC:0000905148-26-000676:0
3,546 shares@ US$34.6221.3% of flowCommon StockSEC:0000905148-26-000678:0
7,607 shares@ US$34.627.5% of flowCommon StockSEC:0000905148-26-000675:0
5,718 shares@ US$36.0147.0% of flowCommon StockSEC:0000905148-26-000498:0
40,000 shares@ US$27.4031.4% of flowCommon StockSEC:0000905148-26-000495:0
25 of 91 declarations
About Rigel Pharmaceuticals Inc
Rigel Pharmaceuticals, Inc. (ticker: RIGL) is a Nasdaq-listed biotechnology company in the United States, with its principal executive offices in South San Francisco, California. Founded in the late 1990s, Rigel was built around small-molecule drug discovery and development, initially focused on signaling pathways relevant to immune, inflammatory, hematologic, and oncologic diseases. Over time, the company has evolved from a pure R&D platform into a commercial-stage biotech with recurring product revenue plus collaboration income. ([rigel.com](https://www.rigel.com/investors/sec-filings/all-sec-filings/content/0001034842-26-000015/0001034842-26-000015.pdf))
Rigel’s current business is anchored by three marketed products and one active development candidate. TAVALISSE (fostamatinib) is approved in the U.S. for adult patients with chronic immune thrombocytopenia who have had an insufficient response to a prior treatment, and it also has international partnering activity. REZLIDHIA (olutasidenib) is approved for relapsed or refractory IDH1-mutated acute myeloid leukemia and remains a key hematology-oncology asset. GAVRETO (pralsetinib), acquired from Blueprint in 2024, is a once-daily RET inhibitor used in certain RET fusion-positive non-small cell lung cancer and advanced thyroid cancer settings. Beyond commercialization, Rigel is advancing R289, an investigational hematology program currently in dose-expansion work in lower-risk myelodysplastic syndromes. ([rigel.com](https://www.rigel.com/investors/sec-filings/all-sec-filings/content/0001034842-26-000015/0001034842-26-000015.pdf))
Read moreShow less
From a market-positioning standpoint, Rigel is a niche player rather than a broad-based pharma company. Its strategy is to compete in targeted rare and specialty disease segments where biomarker-driven medicines can command clinical differentiation, while leveraging a relatively lean commercial footprint. The company’s SEC filings emphasize that its products compete against established therapies and emerging pipeline assets, particularly in ITP, AML, and RET-altered cancers. In practical terms, that means Rigel’s investment case depends on maintaining product uptake, defending pricing and access, and continuing to generate supportive clinical evidence. ([rigel.com](https://www.rigel.com/investors/sec-filings/all-sec-filings/content/0001034842-26-000015/0001034842-26-000015.pdf))
Recent developments have been meaningful. Rigel reported approximately $294.3 million of total revenue in 2025, including $232.0 million of net product sales, and guided to roughly $275 million to $290 million of total revenue for 2026 with expected full-year profitability. The company also published final five-year data for REZLIDHIA in 2025, announced progress on R289 in March 2026, and highlighted a U.S. regulatory update for GAVRETO at the end of 2025. For international equity investors, RIGL is best viewed as a U.S.-listed commercial biotech with improving financial scale, a focused hematology/oncology franchise, and material event-driven upside and risk tied to clinical and regulatory execution. ([rigel.com](https://www.rigel.com/investors/sec-filings/all-sec-filings/content/0001034842-26-000016/0001034842-26-000016.pdf))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
